Evotec SE — Regulatory Filings 2001

Apr 10, 2001

News Details

Ad-hoc | 10 April 2001 08:54

Ad hoc-Service: EVOTEC BioSystems AG english

Ad hoc announcement processed and transmitted by DGAP. The issuer has the sole responsibility of this announcement. ——————————————————————————– Evotec OAI Signs Technology Agreement With Celltech Hamburg, Germany / Abingdon, UK, April 10, 2001 – Evotec OAI, Hamburg, Germany (EVOTEC BioSystems AG, Neuer Markt: EVT) has signed a technology agreement with Celltech Group plc (LSE: CCH, NYSE: CLL). Evotec OAI will apply its proprietary VLiP (virus-like particle) technology to two of Celltech’s GPCR (G-Protein Coupled Receptor) targets. For both targets, Evotec OAI will express the protein, develop screening assays and produce concentrated VLiP protein for further characterisation. The VLiP technology offers the potential to develop robust generic assays and is an ideal tool for generating cell-based assays. A VLiP particle carries the receptor of interest at high concentration in its normal physiological environment. This innovative technology eliminates many conventional problems that now occur when cellular systems are used in drug discovery, such as inaccuracy, a lack of reproducibility or instability. On successful completion of this evaluation, Celltech will have the option to obtain from Evotec OAI a non-exclusive licence to use Evotec OAI’s VLiP technology. This licence agreement will include an upfront payment and annual fee, as well as milestone payments for any drug products discovered through the use of the VLiP technology. EVOTEC BioSystems AG Anne Hennecke, Investor Relations Phone:+49-40-56081286 Fax:+49-40-56081333 E-mail: anne.hennecke@evotecoai.com end of ad hoc announcement, (c) DGAP 10.04.2001 ——————————————————————————– WKN: 566480; Index: NEMAX-50 Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 100854 Apr 01